Estimated effectiveness of 2024-2025 COVID-19 vaccination against severe COVID-19
Peer-Reviewed Publication
Updates every hour. Last Updated: 1-Jun-2026 10:16 ET (1-Jun-2026 14:16 GMT/UTC)
A University of Calgary-led international research team has identified a genetic factor that may explain why people respond so differently to opioid pain medications, and why some individuals face greater risk of side effects including dependency.
The study, published in Neuron, involved researchers from the Faculty of Veterinary Medicine (UCVM), Cumming School of Medicine (CSM), and Hotchkiss Brain Institute (HBI), and provides new clinical insight that could lead to personalized strategies to optimize pain management.
Illumina (NASDAQ: ILMN) today announced a sequencing agreement with the San Diego Zoo Wildlife Alliance (SDZWA)’s Frozen Zoo®. The 50-year-old biobank is the world’s most comprehensive and diverse collection of living cells from threatened and endangered species across the animal kingdom. Illumina will sequence up to 4,000 samples representing 1,300 species in the Frozen Zoo®. Genomic insights will be applied to real-world conservation challenges and efforts to safeguard animal species worldwide. A subset of samples will be used for groundbreaking multiomic research, geared toward unlocking vital insights into wildlife medicine, evolutionary biology, and biodiversity preservation.
The protein Dickkopf 3 plays a key role in the development of radiation-induced fibroses – and could be a promising target for novel therapies.
Followed by the development and regulatory milestone payment of USD 3 million in July 2025, Insilico received an additional milestone payment of USD 5 million from Menarini Group after first-in-patient dosing in a Phase 1 trial of MEN2501, highly differentiated small molecule KIF18A inhibitor in development for chromosomally unstable solid tumors designed using Insilico’s generative AI engine.